Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human

References

• Alonen A, Finel M, Kostiainen R. (2008). The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol 76:763–772.
   PubMed Web of Science ®Google Scholar
• Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I. (2009). Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. Xenobiotica 39:523–533.
   PubMed Web of Science ®Google Scholar
• Borlak J, Gasparic A, Locher M, Schupke H, Hermann R. (2006). N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metab Clin Exp 55:711–721.
   PubMedGoogle Scholar
• Chiu SH, Huskey SW. (1998). Species differences in N-glucuronidation. Drug Metab Dispos 26:838–847.
   PubMed Web of Science ®Google Scholar
• Doig MV, Clare RA. (1991). Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine. J Chromatogr 554:181–189.
   PubMed Web of Science ®Google Scholar
• Dula E, Bukofzer S, Perdok R, George M; Apomorphine SL Study Group. (2001). Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 39:558–3; discussion 564.
   PubMedGoogle Scholar
• EMEA. (2006). Non-renewal of the marketing authorisation in the European Union. EMEA Website www.emea.europa.eu.
   Google Scholar
• Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S. (2002). Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 42:175–182.
   PubMed Web of Science ®Google Scholar
• Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT. (1995). Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 25:185–197.
   PubMed Web of Science ®Google Scholar
• Gobry V BG, Carrupt P-A, Testa B, Girault HH. (2000). Physicochemical Characterization of Sildenafil: Ionization, Lipophilicity Behaviour, and Ionic-Partition Diagram Studied by Two-Phase Titration and Electrochemistry. Helvetica Chimica Acta 83:1465–1474.
   Google Scholar
• Harrison A, Betts A, Fenner K, Beaumont K, Edgington A, Roffey S, Davis J, Comby P, Morgan P. (2004). Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations. Drug Metab Dispos 32:197–204.
   PubMed Web of Science ®Google Scholar
• Hawes EM. (1998). N+-glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Drug Metab Dispos 26:830–837.
   PubMed Web of Science ®Google Scholar
• Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–1479.
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. (2005). Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103–112.
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A. (2009). Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82–89.
   PubMed Web of Science ®Google Scholar
• Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, Maurel P, Fabre G. (2008). Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos 36:851–862.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
   PubMed Web of Science ®Google Scholar
• Maclennan KM, Boshier A, Wilton LV, Shakir SA. (2006). Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. BJU Int 98:125–131.
   PubMed Web of Science ®Google Scholar
• Montorsi. (2002). The Role of Apomorphine SL in the Treatment of Erectile Dysfunction. European Urology Supplements 1:4–11.
   Google Scholar
• Ogura K, Ishikawa Y, Kaku T, Nishiyama T, Ohnuma T, Muro K, Hiratsuka A. (2006). Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 71:1358–1369.
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–2378.
   PubMed Web of Science ®Google Scholar
• Pinter MM, Pogarell O, Oertel WH. (1999). Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatr 66:436–441.
   PubMed Web of Science ®Google Scholar
• Pissarnitski D. (2006). Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6. Med Res Rev 26:369–395.
   PubMed Web of Science ®Google Scholar
• Rambeck B, Wolf P. (1993). Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 25:433–443.
   PubMed Web of Science ®Google Scholar
• Stopher D, McClean S. (1990). An improved method for the determination of distribution coefficients. J Pharm Pharmacol 42:144.
   PubMed Web of Science ®Google Scholar
• Van der Graaf PH WC, Baxter AD, Cook AS, Wong SKF. (2003). Selective dopamine D3 receptor agonists for the treatment of sexual dysfunction. PCT Int. Appl WO2003051370.
   Google Scholar